BlueCross BlueShield Federal Employee Program

(ustekinumab) STELARA PRIOR APPROVAL REQUEST

Send completed form to:
FAX: 855-895-3504
FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form

Patient Information (required)			**Provider Information (required)**		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: **R**			Physician Signature:		
PHYSICIAN COMPLETES					

Stelara (ustekinumab)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its **entirety** for processing

1. Has the patient been on Stelara continuously for the last **6 months**, excluding samples? ***Please select answer below:***
   ❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the questions on **PAGE 4**
   ❑ **NO –** this is **INITIATION** of therapy, please answer the questions below:
2. Is this request for brand or generic? ❑ Brand ❑ Generic
3. Has the patient been tested for latent tuberculosis (TB)? ❑Yes* ❑No
   If YES, was the result of the test positive or negative for TB infection? ❑ Negative ❑ Positive*
   If POSITIVE, has the patient completed treatment or is the patient currently receiving treatment for latent TB? ❑Yes ❑No
4. Does the patient have any active infections including active TB or hepatitis B virus (HBV) infection? ❑Yes ❑No
5. Will the patient be given live vaccines while on Stelara? ❑Yes ❑No
6. Will Stelara be used in combination with another biologic *disease-modifying antirheumatic drug (DMARD) or targeted synthetic DMARD? ❑Yes* ❑No
   If YES, please specify: _____
   DMARDs: Actemra, Avsola, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Ilumya, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Renflexis, Riabni, Rinvoq, Rituxan, Ruxience, Siliq, Simponi/Simponi Aria, Skyrizi, Taltz, Tremfya, Truxima, and Xeljanz/Xeljanz XR
7. What is the patient's diagnosis?
   ❑ Crohn's Disease (CD)
   a. Does the patient have a diagnosis of moderate to severely active Crohn's disease? ❑Yes ❑No
   b. Does the patient have a contraindication to or have they had either an inadequate response or intolerance to at least one conventional therapy option? ❑Yes ❑No
   c. Will the patient's first dose be given an IV infusion? ❑Yes ❑No
   d. What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***
   ❑**55kg (121lbs) or less**: Does the prescriber agree to administer 260mg for the initial IV infusion? ❑Yes ❑No
   ❑**Greater than 55kg (121lbs) to 85kg (187lbs)**: Does the prescriber agree to administer 390mg for the initial IV infusion? ❑Yes ❑No
   ❑**Greater than 85kg (187lbs)**: Does the prescriber agree to administer 520mg for the initial infusion? ❑Yes ❑No
   e. Following the initial IV infusion, does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No
   f. **Standard/Basic Option patient, for claims adjudicated through the pharmacy benefit:** Is Stelara being requested as a change from Cimzia so the member can access their copay benefit? ❑Yes ❑No

PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL DIAGNOSES

BlueCross BlueShield Federal Employee Program

(ustekinumab) STELARA PRIOR APPROVAL REQUEST

Send completed form to: FAX: 855-895-3504 FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form

PAGE 2 - PHYSICIAN COMPLETES

Patient Name: _____ **DOB:** _____ **Patient ID: R** _____

❑ Plaque Psoriasis (PsO)

a. Does the patient have a diagnosis of moderate to severe plaque psoriasis? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to conventional systemic therapy? ***Please select answer below:***

❑ Inadequate response ❑ Intolerance or contraindication ❑ Has not tried conventional systemic therapy

c. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to phototherapy? ***Please select answer below:***

❑ Inadequate response ❑ Intolerance or contraindication ❑ Has not tried phototherapy

d. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

e. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**100kg (220lbs) or less**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (221lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

❑ Psoriatic Arthritis (PsA)

a. Does the patient have a diagnosis of active psoriatic arthritis? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to a three month trial of at least one conventional DMARD? ❑Yes ❑No

c. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

d. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than or equal to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs)**: Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

PLEASE PROCEED TO PAGE 3 FOR ADDITIONAL DIAGNOSES

BlueCross BlueShield Federal Employee Program

(ustekinumab) STELARA PRIOR APPROVAL REQUEST

Send completed form to:
FAX: 855-895-3504
FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form

PAGE 3 - PHYSICIAN COMPLETES

Patient Name: _____ DOB: _____ Patient ID: R _____

❑ Ulcerative Colitis (UC)

a. Does the patient have a diagnosis of moderate to severely active ulcerative colitis? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to at least one conventional therapy option? ❑Yes ❑No

c. Will the patient's first dose be given as an IV infusion? ❑Yes ❑No

d. What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**55kg (121lbs) or less**: Does the prescriber agree to administer 260mg for the initial IV infusion? ❑Yes ❑No

❑**Greater than 55kg (121lbs) to 85kg (187lbs)**: Does the prescriber agree to administer 390mg for the initial IV infusion? ❑Yes ❑No

❑**Greater than 85kg (187lbs)**: Does the prescriber agree to administer 520mg for the initial infusion? ❑Yes ❑No

e. Following the initial IV infusion, does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No

f. **Standard/Basic Option patient, <u>for claims adjudicated through the pharmacy benefit</u>:** Is Stelara being requested as a change from Zeposia so the member can access their copay benefit? ❑Yes ❑No

❑ Other diagnosis ***(please specify):*** _____

BlueCross BlueShield Federal Employee Program

(ustekinumab) STELARA PRIOR APPROVAL REQUEST

Send completed form to:
FAX: 855-895-3504
FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form

Patient Information (required)			**Provider Information (required)**		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: **R**			Physician Signature:		
PHYSICIAN COMPLETES					

CONTINUATION OF THERAPY (PA RENEWAL)

Stelara (ustekinumab)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its **entirety** for processing

1. Has the patient been on Stelara continuously for the last **6 months**, excluding samples? ***Please select answer below:***
   ❑**NO** – this is **INITIATION** of therapy, please answer the questions on **PAGE 1**
   ❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the questions below:
2. Is this request for brand or generic? ❑Brand ❑Generic
3. Has the patient's condition improved or stabilized with Stelara? ❑Yes ❑No
4. Does the patient have any active infections including active tuberculosis (TB) and hepatitis B virus (HBV) infection? ❑Yes ❑No
5. Will the patient be given live vaccines while on Stelara? ❑Yes ❑No
6. Will Stelara be used in combination with another biologic *disease-modifying antirheumatic drug (DMARD) or targeted synthetic DMARD? ❑Yes* ❑No
   If YES, please specify: _____
   DMARDs: Actemra, Avsola, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Ilumya, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Renflexis, Riabni, Rinvoq, Rituxan, Ruxience, Siliq, Simponi/Simponi Aria, Skyrizi, Taltz, Tremfya, Truxima, and Xeljanz/Xeljanz XR
7. What is the patient's diagnosis?
   ❑Crohn's Disease (CD)
   a. Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No
   ❑Plaque Psoriasis (PsO)
   a. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***
      ❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No
      ❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No
      ❑**Greater than 100kg (220lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No
   b. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***
      ❑**100kg (220lbs) or less**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No
      ❑**Greater than 100kg (220lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

PLEASE PROCEED TO PAGE 4 FOR ADDITIONAL DIAGNOSES

BlueCross BlueShield Federal Employee Program

STELARA
PRIOR APPROVAL REQUEST

Send completed form to:
FAX: 855-895-3504
FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form

PAGE 5 – PHYSICIAN COMPLETES

Patient Name: _____ **DOB:** _____ **Patient ID: R** _____

❑Psoriatic Arthritis (PsA)

a. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

b. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than or equal to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs)**: Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑Ulcerative Colitis (UC)

a. Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No

❑Other diagnosis ***(please specify):*** _____